Table 2.
Warfarin dose | mg/week | Ref. |
---|---|---|
Mean therapeutic dose | 14.4 | – |
Algorithm-predicted dose‡ | ||
Sconce et al. (2005) | 47.6 | [41] |
Wadelius et al. (2005) | 49.7 | [21] |
Herman et al. (2006) | 42.5 | [51] |
Takahashi et al. (2006) | 50.3 | [5] |
Tham et al. (2006) | 32.9 | [52] |
Anderson et al. (2007) | 45.8 | [53] |
Miao et al. (2007) | 49.1 | [54] |
Zhu et al. (2007) | 52.2 | [40] |
Gage et al. (2008) | 34.6 | [16] |
Schelleman et al. (2008) (C) | 41.9 | [17] |
Schelleman et al. (2008) (AA) | 28.4 | [17] |
Schelleman et al. (2008) (C + AA) | 41.5 | [17] |
Wu et al. (2008) | 24.9 | [20] |
Klein et al. (2009) | 35.4 | [6] |
Wadelius et al. (2009) | 50.1 | [22] |
Based on the following genotypes: CYP2C9: *1/*1; VKORC1 (Accession Number AY587020) g.-4931T>C (381T>C): T/C, g.-1639G>A (3673G>A): G/G, g.1173C>T (6484C>T): C/C, g.2255C>T (7566C>T): C/T, g.3730G>A (9041G>A): G/G; F7 g.-401G>T: G/G; APOE: ε2/ε3.
AA: African–American; C: Caucasian.